Parnell Pharmaceuticals Holdings Ltd. operates as an integrated pharmaceutical company that develops animal health solutions. It operates in four segments: Companion Animal, Production Animal U.S., Production Animal Rest of World, and Manufacturing Operations. The company's marketed products include reproductive hormone products comprising estroPLAN and GONAbreed that are used in breeding programs to increase pregnancy rates in dairy and beef cows; Zydax, a patented disease-modifying product for the treatment of osteoarthritis (OA) in dogs and horses; Glyde, a nutraceutical product is a combination of glycoaminoglycans for the treatment of OA in dogs; and Tergive, an injectable NSAID that contains carprofen. It is also developing GONADOPRO combination formulation of gonadorelin acetate; PAR081, a propofol-based product for general anesthesia and sedation in dogs and cats; PAR101 to treat laminitis in horses and diabetes in dogs; PAR121 for bone-related diseases and injuries in dogs, cats, and horses; PAR122 for atopic dermatitis and other dermatological conditions; and PAR061, an injectable antibiotic prodrug. The company markets its products in Australia, New Zealand, Singapore, Hong Kong, Dubai, the United States, Canada, the Middle East, and Africa. The company was formerly known as Parnell Pharmaceuticals Holdings Pty Ltd and changed its name to Parnell Pharmaceuticals Holdings Ltd. in April 2014. The company was founded in 1986 and is headquartered in Alexandria, Australia.
